 Connection
Katy Trinkley to Treatment Outcome
This is a "connection" page, showing publications Katy Trinkley has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.216 |
|
|
|
-
Derington CG, King JB, Delate T, Botts SR, Kroehl M, Kao DP, Trinkley KE. Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. PLoS One. 2020; 15(12):e0243371.
Score: 0.056
-
Trinkley KE, Sturm AM, Porter K, Nahata MC. Efficacy and Safety of Atypical Antipsychotics for Behavioral and Psychological Symptoms of Dementia Among Community Dwelling Adults. J Pharm Pract. 2020 Feb; 33(1):7-14.
Score: 0.047
-
Tsai T, Kroehl ME, Smith SM, Thompson AM, Dai IY, Trinkley KE. Efficacy and safety of twice- vs once-daily dosing of lisinopril for hypertension. J Clin Hypertens (Greenwich). 2017 Sep; 19(9):868-873.
Score: 0.044
-
VanderWeide LA, Smith SM, Trinkley KE. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. J Clin Pharm Ther. 2015 Feb; 40(1):1-6.
Score: 0.037
-
Lu AD, Chavez C, Daugherty SL, Dhar P, Derington CG, Everhart R, Morse EF, Novins-Montague S, Trinkley KE, Waughtal JM, Zucker R, Carey E, Bull S, Peterson PN, Ho PM. Using artificially intelligent text messaging to improve health behaviors to reduce cardiovascular risk: study protocol for a pragmatic randomized control trial. Trials. 2026 Feb 20; 27(1).
Score: 0.020
-
Sturm AS, Trinkley KE, Porter K, Nahata MC. Efficacy and safety of atypical antipsychotics for behavioral symptoms of dementia among patients residing in long-term care. Int J Clin Pharm. 2018 Feb; 40(1):135-142.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|